Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Site-1 protease–derived soluble (pro)renin receptor targets vasopressin receptor 2 to enhance urine concentrating capability
Fei Wang, Chuanming Xu, Renfei Luo, Kexin Peng, Nirupama Ramkumar, Shiying Xie, Xiaohan Lu, Long Zhao, Chang-Jiang Zuo, Donald E. Kohan, Tianxin Yang
Fei Wang, Chuanming Xu, Renfei Luo, Kexin Peng, Nirupama Ramkumar, Shiying Xie, Xiaohan Lu, Long Zhao, Chang-Jiang Zuo, Donald E. Kohan, Tianxin Yang
View: Text | PDF
Research Article Nephrology

Site-1 protease–derived soluble (pro)renin receptor targets vasopressin receptor 2 to enhance urine concentrating capability

  • Text
  • PDF
Abstract

The antidiuretic hormone vasopressin (AVP), acting through its type 2 receptor (V2R) in the collecting duct (CD), critically controls urine concentrating capability. Here, we report that site-1 protease–derived (S1P-derived) soluble (pro)renin receptor (sPRR) participates in regulation of fluid homeostasis via targeting V2R. In cultured inner medullary collecting duct (IMCD) cells, AVP-induced V2R expression was blunted by a PRR antagonist, PRO20; a PRR-neutralizing antibody; or a S1P inhibitor, PF-429242. In parallel, sPRR release was increased by AVP and reduced by PF-429242. Administration of histidine-tagged sPRR, sPRR-His, stimulated V2R expression and also reversed the inhibitory effect of PF-429242 on the expression induced by AVP. PF-429242 treatment in C57/BL6 mice impaired urine concentrating capability, which was rescued by sPRR-His. This observation was recapitulated in mice with renal tubule–specific deletion of S1P. During the pharmacological or genetic manipulation of S1P alone or in combination with sPRR-His, the changes in urine concentration were paralleled with renal expression of V2R and aquaporin-2 (AQP2). Together, these results support that S1P-derived sPRR exerts a key role in determining renal V2R expression and, thus, urine concentrating capability.

Authors

Fei Wang, Chuanming Xu, Renfei Luo, Kexin Peng, Nirupama Ramkumar, Shiying Xie, Xiaohan Lu, Long Zhao, Chang-Jiang Zuo, Donald E. Kohan, Tianxin Yang

×

Figure 11

Effect of sPRR-His infusion on urine osmolality response to acute arginine vasopressin (AVP) treatment in PRR KO mice.

Options: View larger image (or click on image) Download as PowerPoint
Effect of sPRR-His infusion on urine osmolality response to acute argini...
Urine was emptied by bladder massage and subjected to measurement of osmolality before and after AVP treatment (720 ng/kg body weight). (A and B) Shown is the ratio of the change in urine osmolality in CD PRR–KO mice (n = 6 mice per group) (A) and RT PRR–KO mice (n = 6-7 mice per group) (B). (C) Twenty-four–hour urinary AVP excretion in floxed, CD PRR–KO/vehicle, and CD PRR–KO/sPRR-His mice (n = 6–8 mice per group). (D) Twenty-four–hour urinary AVP excretion in floxed, RT PRR–KO/vehicle,and RT PRR–KO/sPRR-His mice (n = 6 mice per group). Statistical significance was determined by using 1-way ANOVA with the Bonferroni test for multiple comparisons. Data are mean ± SEM. *P < 0.05 vs. control; #P < 0.05 vs. PRR-KO mice alone.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts